TAK Takeda Pharmaceutical
- Official Name: Takeda Pharmaceutical Company Limited
- Headquarters: 75 Sidney Street Cambridge, MASSACHUSETTS 02139, US
- CEO: Christophe Weber
- Website: takeda.com
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-15 | 1R | Won by 0.412 | (2.652) - (3.064) | ||
| 2025-07-18 | 1 | Won by 5.310 | 2.678 - (2.632) | ||
| 2025-07-25 | 2 | Won by 4.627 | 3.459 - (1.168) | ||
| 2025-07-29 | 2R | Lost by 0.071 | 0.585 - 0.656 | ||
| 2025-08-01 | 3 | Won by 15.735 | 9.652 - (6.083) | ||
| 2025-08-08 | 4 | Won by 9.104 | 5.092 - (4.012) | ||
| 2025-08-15 | 5 | Won by 3.917 | 3.917 - 0.000 | ||
| 2025-08-22 | 6 | Won by 1.498 | 3.094 - 1.596 | ||
| 2025-08-29 | 7 | Lost by 2.731 | (3.609) - (0.878) | ||
| 2025-09-05 | 8 | Won by 4.622 | 3.384 - (1.238) | ||
| 2025-09-12 | 9 | Won by 2.644 | (2.312) - (4.956) | ||
| 2025-09-19 | 10 | Lost by 2.276 | (0.274) - 2.002 | ||
| 2025-09-26 | 11 | Lost by 0.354 | (2.378) - (2.024) | ||
| 2025-10-03 | 12 | Lost by 3.937 | (0.874) - 3.063 | ||
| 2025-10-10 | 13 | Lost by 0.976 | (6.000) - (5.024) | ||
| 2025-10-17 | 14 | Lost by 1.468 | 2.612 - 4.080 | ||
| 2025-10-24 | 15 | Lost by 4.452 | (0.228) - 4.224 |
Latest News
Benzinga - 2026-09-29
Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trial
ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial to compare the efficacy and safety of elritercept to placebo in patients with myel...
Yahoo - 2026-09-27
Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC
Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercializ...
Yahoo - 2026-09-25
Basecamp raises $140M before the clinic; J&J and Compass’ potential rivalry
Some of the biggest news and trends captured in PharmaVoice’s newsletter this week. Sign up here to receive the newsletter daily. Another big AI h...
Show more
SeekingAlpha - 2026-09-24
AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions
Benzinga - 2026-09-21
Nvidia-Backed AI Drug Discovery Company Iambic Therapeutics Files for Nasdaq IPO, to Use Proceeds for Cancer Drug Development
Yahoo - 2026-09-18
Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?
SeekingAlpha - 2026-09-18
5 Undervalued Oncology Stocks Wall Street Is Overlooking
Yahoo - 2026-09-18
Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems
Yahoo - 2026-09-17
Takeda Pharmaceutical (TAK) Gets Priority Review. Can Zasocitinib Win in Psoriasis?
Benzinga - 2026-09-17
Full Transcript: Takeda Pharmaceutical Co Q1 2026 Earnings Call
Yahoo - 2026-09-16
Do Novavax’s (NVAX) New Partnerships Offset Policy Risks From The Protecting Approved Care Act?
Yahoo - 2026-09-15
Hummingbird Bioscience Appoints Dr. James Garner as President
SeekingAlpha - 2026-09-14
Takeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Yahoo - 2026-09-14
Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Monday Trading
Yahoo - 2026-09-14
Best Value Stocks to Buy for September 14th
Yahoo - 2026-09-14
Best Income Stocks to Buy for September 14th
Benzinga - 2026-09-13
Takeda's Zasocitinib Shows About 70% Of Patients Achieving Clear Or Almost Clear Skin At Week 16 In Phase 3 LATITUDE PsO Studies Of Nearly 3,000 Patients
SeekingAlpha - 2026-09-11
BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity
Yahoo - 2026-09-10
Andy Plump, architect of Takeda’s R&D overhaul, to retire next year
Yahoo - 2026-09-09
Trialbee to Present with Takeda, Showcase AI for Clinical Sites, and Unveil AI-Powered Patient Screening at DPHARM 2026
Yahoo - 2026-09-09
Onco360® Has Been Selected as Part of an Ultra-Narrow Specialty Pharmacy Network for MIMRYLO™ (rusfertide)
Benzinga - 2026-09-09
Takeda's Phase 3 Trial Of Oveporexton's Data Published In New England Journal Of Medicine To Treat Narcolepsy Type 1; Oveporexton Generally Well-Tolerated With Consistent Safety Profile
Yahoo - 2026-09-08
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
Yahoo - 2026-09-07
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight
Yahoo - 2026-09-04
MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?
Yahoo - 2026-09-02
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
Yahoo - 2026-09-02
2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB
Yahoo - 2026-09-01
Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story?
Yahoo - 2026-09-01
Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities
Yahoo - 2026-09-01
The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following FDA Approval Of MIMRYLO And Takeda Milestones
SeekingAlpha - 2026-09-01
Exelixis: "Hold" On Zanzalintinib Subpopulation Miss And STELLAR-304 2H 2026 Data
Yahoo - 2026-08-31
Chris Benecchi Named Inventiva’s New Chief Operating Officer
Yahoo - 2026-08-31
Sector Update: Healthcare Stocks Decline Late Afternoon
Yahoo - 2026-08-31
Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment
Yahoo - 2026-08-31
Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug
SeekingAlpha - 2026-08-31
Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know
Yahoo - 2026-08-31
FDA OKs Takeda, Protagonist drug for rare blood cancer
Yahoo - 2026-08-29
How Expanded Nuvaxovid Royalties and Partner-led Execution Could Shape Novavax’s (NVAX) Investment Narrative
Yahoo - 2026-08-28
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
Yahoo - 2026-08-28
Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
Yahoo - 2026-08-26
Pure Strategies Announces "Day of Action" Full Day Program during Climate Week NYC - September 23, 2026
Yahoo - 2026-08-24
KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
Yahoo - 2026-08-24
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
Benzinga - 2026-08-23
Takeda’s ORZEYFUL Wins Japan Approval For Narcolepsy Type 1 After Phase 3 Studies Show Significant Improvements Across Evaluated Symptoms
Yahoo - 2026-08-20
Ascentage Pharma Group International H1 Earnings Call Highlights
SeekingAlpha - 2026-08-19
Silence Therapeutics: Making Some Recent Noise
Benzinga - 2026-08-13
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
Benzinga - 2026-08-13
Vinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’
Benzinga - 2026-08-10
Department Of Veterans Affairs Awards Takeda $5.6B Contract for Drugs And Biologicals Through 2031
SeekingAlpha - 2026-08-07
Takeda's Pipeline Looks Encouraging, But Generic Erosion Is A Near-Term Concern
Yahoo - 2026-08-06
Takeda nets first-in-class advantage on narcolepsy drug’s FDA go-ahead
Yahoo - 2026-08-06
Takeda approval ushers in new wave of sleep drugs
Benzinga - 2026-08-06
Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval
Yahoo - 2026-08-06
Exelixis Inc (EXEL) (Q2 2026) Earnings Call Highlights: Strong Cabozantinib Growth Offsets NET ...
Yahoo - 2026-08-05
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
Benzinga - 2026-08-05
Takeda's ORZEYFUL Wins FDA Approval As First Orexin Therapy For Narcolepsy Type 1; U.S. Launch Planned Following DEA Scheduling
Yahoo - 2026-08-05
AC Immune First Half 2026 Financial and Corporate Update
SeekingAlpha - 2026-08-03
Takeda Pharmaceutical Company Limited (TAK) Q1 2026 Earnings Call Transcript
Yahoo - 2026-07-31
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate
Benzinga - 2026-07-30
Keros Therapeutics To Receive $20M Milestone Payment From Takeda Under Elritercept Licensing Terms After Dosing First Patient In The ELRiSE MDS Trial
SeekingAlpha - 2026-07-30
Takeda Pharmaceutical Company Limited (TAK) Q1 2027 Earnings Call Transcript
Yahoo - 2026-07-30
Takeda Pharmaceutical Q1 Earnings Call Highlights
Benzinga - 2026-07-30
CORRECTION: Takeda Pharmaceutical Co Affirms FY2026 Adj EPS Guidance of $3.01 vs $1.57 Est; Affirms FY2026 Sales Guidance of $29.585B vs $28.950B Est
Yahoo - 2026-07-30
Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track
SeekingAlpha - 2026-07-30
Takeda Pharmaceutical Company Limited 2027 Q1 - Results - Earnings Call Presentation
Benzinga - 2026-07-29
Takeda Pharmaceutical Co Affirms FY2026 GAAP EPS Guidance of $0.66; Affirms FY2026 GAAP Sales Guidance of $29.585B
Benzinga - 2026-07-29
Takeda Pharmaceutical Q1 Adj. EPS $0.48 Beats $0.39 Estimate, Sales $7.655B Beat $7.060B Estimate
SeekingAlpha - 2026-07-28
Incyte: From Buy To Hold After A 93% Rally (Rating Downgrade)
Yahoo - 2026-07-26
How New Phase 3 Psoriasis Data For Zasocitinib At Takeda Pharmaceutical (TSE:4502) Has Changed Its Investment Story
Yahoo - 2026-07-26
Takeda Pharmaceutical (TSE:4502) Reports New Phase 3 Psoriasis Data, Is The 10% Discount Enough?
Yahoo - 2026-07-24
Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading
Benzinga - 2026-07-17
Oral Psoriasis Drug From Takeda Demonstrates Strong Skin Clearance in Trials
Yahoo - 2026-07-16
Change in Siegfried's Management Team
Benzinga - 2026-07-16
World's First End-To-End AI Drug Developer To Power Into Black On Lucrative Partnerships
Yahoo - 2026-07-15
Will Recent Setbacks Impact Growth Prospects of DNLI Stock?
Yahoo - 2026-07-13
Takeda and Indonesia partner on plasma-derived therapies
Yahoo - 2026-07-13
Moderna, Takeda and Capricor on the verge of notching big drug approvals
SeekingAlpha - 2026-07-08
A New Look At Legend Biotech: Plenty Of Upside For Carvykti
Benzinga - 2026-07-02
Takeda Makes Fresh AI Drug Discovery Bet With Insilico Medicine
SeekingAlpha - 2026-07-02
Ascendis Pharma: Behind The Stock Surge
SeekingAlpha - 2026-06-26
Jazz Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)
Benzinga - 2026-06-24
This $300 Million Biotech May Be Deeply Mispriced: Analyst
SeekingAlpha - 2026-06-24
Takeda Pharmaceutical Company Limited (TAK) Shareholder/Analyst Call - Slideshow
Benzinga - 2026-06-23
Takeda Canada Announces Topline Results For Phase 3, Randomized, Multicenter, Double-Blind Study Comparing Zasocitinib To Deucravacitinib In Adults With Plaque Psoriasis
Benzinga - 2026-06-12
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data
SeekingAlpha - 2026-06-11
Takeda Pharmaceutical: The Downside Was Forecastable
Benzinga - 2026-06-11
Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med
Benzinga - 2026-06-11
Takeda Says Zasocitinib (TAK-279) Demonstrated Statistical Superiority Over Deucravacitinib In Moderate-To-Severe Plaque Psoriasis Patients
Benzinga - 2026-06-09
FDA Accepts Review Of Takeda's Supplemental Biologics License Application For intravenous ENTYVIO
SeekingAlpha - 2026-05-20
Takeda Pharmaceutical Company Limited (TAK) Q4 FY2025 Earnings Call Transcript
Benzinga - 2026-05-19
Jury Hits Takeda With $885 Million Antitrust Verdict
SeekingAlpha - 2026-05-18
Takeda's Rich Pipeline Optionality Is Worth A 'Buy'
Yahoo - 2026-05-15
Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year
Yahoo - 2026-05-15
Takeda Pharmaceutical Q4 Earnings Call Highlights
Yahoo - 2026-05-15
Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers
Yahoo - 2026-05-14
Veeva Commercial Summit to Feature Biopharma's AI Successes and the Path to Agentic Commercial
Yahoo - 2026-05-13
Takeda's Next Wave Of Drugs Has Investors Watching Closely
Yahoo - 2026-05-13
Japan Regenerative Medicine Market Trends and Forecasts to 2035 Featuring Astellas Pharma, Fujifilm, JCR Pharmaceuticals, Sumitomo Pharma, Takeda, and Terumo
SeekingAlpha - 2026-05-13
Takeda Pharmaceutical Company Limited (TAK) Q4 2026 Earnings Call Transcript
SeekingAlpha - 2026-05-13
Takeda Pharmaceutical Company Limited 2026 Q4 - Results - Earnings Call Presentation
Benzinga - 2026-05-13
Earnings Scheduled For May 13, 2026
Benzinga - 2026-05-13
Takeda Pharmaceutical Co Sees FY2026 GAAP EPS $0.66.
Benzinga - 2026-05-13
Takeda Pharmaceutical Co Sees FY2026 Adj EPS $3.01; Sees Sales $29.585B
Yahoo - 2026-05-13
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
Benzinga - 2026-05-13
Takeda Pharmaceutical Q4 Adj. EPS $0.28 Beats $0.21 Estimate, Sales $6.978B Miss $7.050B Estimate
Yahoo - 2026-05-11
Takeda Pharmaceutical (TSE:4502) Valuation Check After Recent Share Price Pullback
Yahoo - 2026-05-08
DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects
Yahoo - 2026-05-06
Timothy P. Walbert Joins Patient Square Capital as a Senior Advisor
Yahoo - 2026-05-05
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update
Yahoo - 2026-05-05
Will the Label Expansion of Asceniv Boost ADMA's Top-Line Growth?
Yahoo - 2026-05-05
Model N Appoints Thomas Gibbs to Board of Directors
Yahoo - 2026-05-05
Zifo's SiEE Boston Summit Charts New Roadmap for 'Practical AI' in Life Sciences, Bridging the Gap Between Business Vision and Lab Reality
Yahoo - 2026-05-05
British Columbia reimburses REVESTIVE® (teduglutide for injection) for the treatment of Short Bowel Syndrome
Yahoo - 2026-05-04
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
Benzinga - 2026-05-04
Takeda Announces That The TAK-881-300 Phase 2/3 Clinical Trial In Patients With Primary Immunodeficiency Disease 1 Met Its Primary Endpoint,
Yahoo - 2026-05-04
Why Denali Therapeutics (DNLI) Is Down 8.2% After Takeda Exits DNL593 Collaboration And Returns Rights
Yahoo - 2026-05-02
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Japanese Stocks Amid Restructuring Drive?
Benzinga - 2026-05-01
Axsome Wins FDA Nod For Expanded Use For Auvelity Beyond Depression
Yahoo - 2026-04-30
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
Yahoo - 2026-04-30
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
Yahoo - 2026-04-29
IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight
Yahoo - 2026-04-28
HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference
Yahoo - 2026-04-24
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
Yahoo - 2026-04-23
SYRE Stock Jumps More Than 70% in a Month: What Is Driving This Rally?
Yahoo - 2026-04-23
Bernstein Upgrades Takeda Pharmaceutical (TAK) to Outperform
Yahoo - 2026-04-22
Will Asceniv Deliver for ADMA in the Upcoming Quarterly Results?
Yahoo - 2026-04-21
Takeda Ends Veritas In Silico Pact As mRNA Focus And Valuation Watched
Yahoo - 2026-04-20
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment
Yahoo - 2026-04-20
KROS Rinvatercept: What to Know Before DMD Phase II Starts
Yahoo - 2026-04-17
DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?
SeekingAlpha - 2026-04-17
Johnson & Johnson: Why I See Downside Ahead
Yahoo - 2026-04-16
Does ADMA Biologics' Growth Story Outweigh Short-Seller Concerns?
SeekingAlpha - 2026-04-13
My Top 4 Pharma Picks Under Rising Geopolitical Risk
Benzinga - 2026-04-06
Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why
Benzinga - 2026-04-05
Reported Friday, Denali Therapeutics Regains Full Rights To DNL593 After Takeda Terminates Collaboration, Phase 1/2 FTD-GRN Trial Results Expected By End Of 2026
Benzinga - 2026-04-01
Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda
Benzinga - 2026-04-01
Axsome Therapeutics Enters Into An Asset Purchase Agreement To Obtain Exclusive Global Rights To TAK-063 (balipodect) From Takeda, Deal Terms Undisclosed
SeekingAlpha - 2026-03-30